Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01897012
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:01.666392+00:00
Published At
2019-01-28T00:00:00+00:00
Record Updated At
2019-01-28
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["MYC Positive", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory Hodgkin Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2019-01-28"
protocolSection.identificationModule.nctId
"NCT01897012"
protocolSection.identificationModule.officialTitle
"A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • MYC Positive (protocolSection.conditionsModule.conditions)
  • Recurrent B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Recurrent Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory B-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Refractory Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.